Approximately, 10–20% of patients with drug eluting stent (DES) in-stent restenosis (ISR) will develop recurrent ISR; yet, the optimal management of recurrent DES-ISR is unknown. We sought to compare the outcomes of recurrent DES-ISR treated with drug eluting balloons (DEB) to those with repeated implantation of new-generation DES. A total of 172 patients with recurrent DES-ISR were enrolled and stratified into two cohorts: the repeated DES implantation (Re-DES) group and the DEB group. The primary endpoint was the 1-year incidence of major adverse cardiovascular events (MACE). Ninety-three patients treated with DEB and 79 patients with Re-DES implantation were analyzed. Both groups had comparable baseline characteristics. Lesser residual stenosis was achieved in the Re-DES group (11.3 ± 3.2% vs. 22.4 ± 4.3%; P = 0.00) than in the DEB group. However, the incidence of MACE and target lesion revascularization (TLR) were less in the DEB group (17.2% vs. 32.9%; P = 0.02 and 15.1% vs. 27.8%; P = 0.04, respectively). For the ≥3 metal-layered DES-ISR subgroup, DEB drastically reduced the incidences of MACE and TLR compared with Re-DES (20.0% vs. 57.9%; P = 0.02 and 16.0% vs. 47.4%; P = 0.04, respectively). Survival analysis demonstrated that MACE-free survival was significantly higher in the DEB group compared with the Re-DES group, whether the metal layers were ≥3 or 2. Multivariate analysis revealed that the risk factors of MACE were diabetes mellitus, ≥3 metal-layered DES ISR, and repeat DES deployment. For recurrent DES-ISR, DEB may improve clinical outcomes compared with Re-DES implantation, especially for ≥3 metal-layered DES-ISR.
The rational length of stay following non-complicated percutaneous coronary intervention (PCI) for Non-ST elevation myocardial infarction (NSTEMI) patients remains controversial. Few studies have examined the impact of early discharge on short-term outcomes in NSTEMI patients, but short-time discharge is not uncommon in real world practice. This study examined the impact of short time discharge following non-complicated PCI on 30-day net adverse clinical events in NSTEMI patients. This retrospective study enrolled 1424 consecutive patients with NSTEMI diagnoses who underwent non-complicated PCI. Of these patients, 432 were discharged early (< 24 h), whereas the remaining 992 NSTEMI patients underwent routine discharge. The primary end points of the study were the net adverse clinical events including major adverse cardiac or cerebral events or access site vascular/bleeding complications within 30 days. The differences between the two groups were analyzed after propensity score matching to reduce selection bias. The incidence of crude 30-day net adverse events was numerically higher in the long-time discharge group at 11.6% (115/992) compared with 8.6% (37/432) in the short-time discharge group, although this difference was not significant (P = 0.09). This difference was mainly due to lesser radial access selected in the long-time discharge group (827/932, 83.4% vs. 387/432, 89.5%, P < 0.0005). After PS matching to balance the access difference, there was no significant difference in the incidence of the events mentioned above between two groups. If an NSTEMI patient undergoes PCI without any procedural or hospital complications, short-time discharge after successful PCI would be feasible and safe in selected NSTEMI patients.
Background and Aims: Treatment of drug‐eluting stents (DES) in‐stent restenosis (ISR) was challenging. Neoatherosclerosis (NA) occurs earlier and more frequently in DES‐ISR. This study aims to analyze the effect of neoatheroma morphology and intervention‐associated neoatheroma intima rupture on intervention strategies and clinical outcomes in patients with DES‐ISR. Methods: We retrospectively analyzed 56 consecutive patients with symptomatic DES‐ISR and optical coherence tomography (OCT) verified in‐stent NA who had been treated by repeat stenting or drug‐coated balloon (DCB). Patients were divided into two groups according to whether there was severe neoatheroma intima rupture (SNIR) after balloon angioplasty. Characteristics of the neointima were analyzed. Intervention strategies and clinical outcomes were compared between the two groups. Results: SNIR occurred in 29 patients after balloon angioplasty. Repeat stenting was more frequent in these patients (48.3% vs. 7.4%, p = 0.009). The incidence of target lesion revascularization (TLR) was significantly higher in patients with SNIR (37.9% vs. 11.1%, p = 0.021), SNIR was an independent risk factors of TLR (HR: 3.997, p = 0.034). In patients with SNIR, repeat stenting significantly reduced the rate of TLR than DCB (14.3% vs. 60.0% p = 0.014). The lipid pool depth and the maximum lipid arc of the neoatheroma were significantly larger and the percentage of the frame with neoatherosclerosis was significantly higher in patients with SNIR (510.1 ± 162.7 vs. 370.7 ± 129.6 µm, p = 0.001; 155.5 ± 41.6 vs. 107.7 ± 44.4 degrees, p = 0.000; and 28.2% ± 14.3% vs. 16.0% ± 9.5%, p = 0.001, respectively). Multivariate logistic regression demonstrated that HbA1C (OR = 1.868, p = 0.044) and time from PCI to ISR (OR = 1.278, p = 0.026) were independent predictors of SNIR. Conclusions: Intervention‐associated severe neoatheroma rupture increased the risk of recurrent TLR, repeat stenting was more effective than DCB in such patients. Neoatherosclerosis with a significant lipid pool is closely related to intervention‐associated SNIR.